ArticleCureus2026
Neuropsychiatric Sequelae of Chronic Rhinosinusitis: A Retrospective Cohort Study Using a Multi-institutional Electronic Health Records Network.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundChronic rhinosinusitis (CRS), a common inflammatory disorder of the sinonasal mucosa, is associated with significant morbidity and impaired quality of life. Emerging evidence suggests a link between systemic inflammation and neuropsychiatric disorders, including depression and suicide risk. This study examines whether phenotypic differences in CRS, specifically CRS with nasal polyps (CRSwNP) and CRS without nasal polyps (CRSsNP), are associated with differing psychiatric outcomes.
objectiveThe objective of this study was to evaluate whether CRSwNP and CRSsNP are differentially associated with suicidality and psychiatric disorders.
methodsA retrospective cohort analysis was conducted using the TriNetX research network. Adults diagnosed with CRSwNP or CRSsNP between 2010 and 2023 were identified via the International Statistical Classification of Diseases and Related Health Problems, 10th Revision (ICD-10) codes. Propensity score matching was used to control for demographics and comorbidities, yielding two matched cohorts (n=130,769 each). Primary outcomes included suicidal ideation and suicide attempts. Secondary outcomes included depression, generalized anxiety disorder, bipolar disorder, schizophrenia, schizoaffective disorder, and psychosis. Risk differences, risk ratios, and odds ratios were calculated with 95% confidence intervals.
resultsPatients with CRSwNP demonstrated significantly lower risks of suicidal ideation (risk ratio (RR) 0.66) and suicide attempt (RR 0.63) compared to those with CRSsNP (all p<0.001). CRSwNP was also associated with lower risks of developing depression (RR 0.80), generalized anxiety disorder (RR 0.75), bipolar disorder (RR 0.72), schizophrenia (RR 0.63), schizoaffective disorder (RR 0.63), and psychosis (RR 0.64), although absolute risk differences were small.
conclusionCRSwNP is associated with a significantly lower risk of several psychiatric disorders compared to CRSsNP, potentially due to differences in underlying inflammatory pathways or treatment effects. These findings support the integration of psychiatric screening in CRS management and warrant further investigation into immune modulation as a potential strategy to reduce neuropsychiatric risk.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.